The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
US House and Senate Committees this week passed legislation to control the way pharmacy benefit managers (PBMs) can profit by increasing drug price. 28 July 2023
French drugmaker Ipsen has reported a 7.2% increase in revenues in the first half of the year, driven in part by newly-acquired medicines Bylvay (odevixibat) and Tazverik (tazemetostat). 27 July 2023
Shares of US pharma major AbbVie were up 3.6% at $147.02 in early trading, after the company announced financial results for the second quarter ended June 30, 2023. 27 July 2023
In anticipation of regulatory clearance for its proposed $43 billion acquisition of Seagen, US pharma giant Pfizer today announced a reorganization of its R&D team to create a leading company in the battle against cancer. 27 July 2023
Belgium’s largest pharma company UCB has posted a downbeat set of financials for the first half of 2023, with revenues falling 11% to 2.6 billion euros ($2.9 billion). 27 July 2023
UK pharma major AstraZeneca this morning revealed that Soliris (eculizumab) has been approved in the European Union (EU) for expanded use. 27 July 2023
Swiss pharmaceutical giant Roche this morning revealed that sales for the first half of 2023 had dropped 2% to 29.78 billion Swiss francs ($33.01 billion), or -8% in franc terms. 27 July 2023
US dermatology specialist Verrica Pharmaceuticals announced the closing of the previously announced $125 million debt financing with OrbiMed, a leading healthcare investment firm. 27 July 2023
Japan’s largest pharma company Takeda today announced strong financial results for the first quarter of fiscal year 2023 (period ended June 30, 2023). The firm’s edged up 0.7% to 4,401 yen following the news. 27 July 2023
The US Food and Drug Administration (FDA) yesterday approved Xdemvy (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis. 26 July 2023
The US Food and Drug Administration (FDA) has granted approval of Balfaxar (prothrombin complex concentrate, human-lans) for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, eg, warfarin) therapy in adult patients with need for urgent surgery or invasive procedures. 26 July 2023
Sales and profits at GSK beat expectations in the second quarter, with the firm reporting respectively a 4% and 8% increase from the same period of last year. 26 July 2023
Swiss clinical-stage biotech AC Immune today announced the appointment of Nuno Mendonca as its new chief medical officer of the neurodegenerative diseases specialist. 26 July 2023
US cell therapy developer SQZ Biotechnologies saw its shares close down almost 6% at $0.10 yesterday, after it revealed that Swiss pharma giant Roche has decided not to excercise its option for HPV 16 positive solid tumors under the SQZ-APC-HPV program. 26 July 2023
Shares in Stoke Therapeutics have fallen by a third after the company announced what it described as “positive new safety and efficacy data” from its early stage trial program for STK-001. 26 July 2023
Barcelona, Spain-based plasma-derived medicine specialist Grifols revealed that its recently concluded Phase IV trial (evaluating a biweekly dosing of Xembify has met its primary endpoint. 26 July 2023
In a change of stance from its earlier proposal, India's Health Ministry has proposed that either the state or central authorities be empowered to regulate drugs and cosmetic manufacture, instead of only the Central Drugs Standard Control Organization (CDSCO). 26 July 2023